Pre-Clinical Models of Sepsis (original) (raw)

References

  1. Fink MP. Another negative clinical trial of a new agent for the treatment of sepsis: Rethinking the process of developing adjuvant treatments for serious infections. Crit Care Med 1995;23:989-991.
    PubMed Google Scholar
  2. Dellinger RP, Opal SM, Rotrosen D From the bench to the bedside: The future of sepsis research. Chest 1997;111:744-753.
    PubMed Google Scholar
  3. Bone RC. Sepsis and controlled clinical trials: The odyssey. Crit Care Med 1995;23:1165-1166.
    PubMed Google Scholar
  4. Piper RD, Cook DJ, Bone RC, Sibbald WJ. Introducing Critical Appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 1996;24:2059-2070.
    PubMed Google Scholar
  5. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DP. Publication bias in clinical research. Lancet 1991;337:867-872.
    PubMed Google Scholar
  6. Stüber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-a concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24:381-384.
    PubMed Google Scholar
  7. Meade MO, Creery D, Marshall JC. Systematic review of outcome measures in randomized trials of mediator-directed therapies in sepsis. Sepsis 1997;1:27-33.
    Google Scholar
  8. Lin E, Lowry SF. The human response to endotoxin. Sepsis 1999; 255-262.
  9. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parrillo JE. Endotoxemia in human septic shock. Chest 1991;99:169-175.
    PubMed Google Scholar
  10. Casey LC, Balk RA, Bone RC. Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-778.
    PubMed Google Scholar
  11. Taveira Da Silva AM, Kaulach HC, Chuidian FS, Lambert DR, Stuffredini AF, Danner RL. Brief report: shock and multiple organ dysfunction after self administration of salmonella endotoxin. N Engl J Med 1993;328:1457-1460.
    PubMed Google Scholar
  12. McCuskey RS, McCuskey PA, Urbaschek R, Urbaschek B. Species differences in Kupffer cells and endotoxin sensitivity. Infect Immun 1984;45:278-280.
    PubMed Google Scholar
  13. Gerard C, Bruyns C, Marchant A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993;177:547-550.
    PubMed Google Scholar
  14. Howard M, Tuchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993;177:1205-1208.
    PubMed Google Scholar
  15. Romani L, Puccetti P, Mencacci A, et al. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans J Immunol 1994;152:3514-3521.
    PubMed Google Scholar
  16. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman RE, Standiford TJ. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995;155:722-729.
    PubMed Google Scholar
  17. Beutler B, Milsark IW, Cerami AC. Pasive immunization against cachectin tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-871.
    PubMed Google Scholar
  18. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin /TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-664.
    PubMed Google Scholar
  19. Takashima K, Tateda K, Matsumoto T, lizawa Y, Nakao M, Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 1997;65:257-260.
    PubMed Google Scholar
  20. Fish RE, Spitzer JA. Continuous infusion of endotoxin from an osmotic pump in the conscious, unrestrained rat: a unique model of chronic endotoxemia. Circ Shock 1984;12:135-149.
    PubMed Google Scholar
  21. Arita H, Ogle CK, Alexander JW, Warden GD. Induction of hypermetabolism in guinea pigs by endotoxin infused through the portal vein. Arch Surg 1988;123:1420-1424.
    PubMed Google Scholar
  22. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979;76:5939-5943.
    PubMed Google Scholar
  23. Morikawa A, Sugiyama T, Kato Y, et al. Apoptotic cell death in the response of D-galactosamine-sensitized mice to lipopolysaccharide as an experimental endotoxic shock model. Infect Immun 1996;64:734-738.
    PubMed Google Scholar
  24. van Helden HP, Kuijpers WC, Steenvoorden D, et al. Intratracheal aerosolization of endotoxin (LPS) in the rat: a comprehensive animal model to study adult (acute) respiratory distress syndrome. Exp Lung Res 1997;23:297-316.
    PubMed Google Scholar
  25. Nathens AB, Bitar R, Bujard M, et al. Pyrrolidine dithiocarbamate attenuates endotoxin-induced lung injury. Am J Resp Cell Mol Biol 1997;17:608-616.
    Google Scholar
  26. Silva AT, Bayston KF, Cohen J. Prophylactic and therapeutic effects of an monoclonal antibody to tumor necrosis factor-a in experimental gram-negative shock. J Infect Dis 1990;162:421-427.
    PubMed Google Scholar
  27. Kullberg BJ, van'T Wout JW, Van Furth R. Role of granulocytes in increased host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun 1990;58:3319-3324.
    PubMed Google Scholar
  28. Wakiyama H, Tsuru S, Hata N, et al. Therapeutic effect of granulocyte colony-stimulating factor and cephem antibiotics against experimental infections in neutropenic mice induced by cyclophosphamide. Clin exp Immunol 1993;92:218-224.
    PubMed Google Scholar
  29. Freeman BD, Correa R, Karzai W, et al. Controlled trials of rG-CSF and CD11b-directed MAb during hyperoxia and E. coli pneumonia in rats. J Appl Physiol 1996;80:2066-2076.
    PubMed Google Scholar
  30. McRitchie DI, Girotti MJ, Glynn MFX, Goldberg JM, Rotstein OD. Effect of systemic fibrinogen depletion on intraabdominal abscess formation. J Lab Clin Med 1991;118:48-55.
    PubMed Google Scholar
  31. Marshall JC, Christou NV, Meakins JL. Small bowel bacterial overgrowth and systemic immunosuppression in experimental peritonitis. Surgery 1988;104:404-411.
    PubMed Google Scholar
  32. Yao YM, Lu LR, Yu Y, et al. Influence of selective decontamination of the digestive tract on cell-mediated immune function and bacteria/endotoxin translocation in thermally injured rats. J Trauma 1997;42:1073-1079.
    PubMed Google Scholar
  33. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res 1990;49:186-196.
    PubMed Google Scholar
  34. Wichterman KA, Baue AE, Chaudry IH. Sepsis and shock-a review of laboratory models and a proposal. J Surg Res 1980;29:189-201.
    PubMed Google Scholar
  35. Wang P, Chaudry IH. A single hit model of polymicrobial sepsis: Cecal ligation and puncture. Sepsis 1999;255-262.
  36. Avila A, Warshawski F, Sibbald WJ, Finley R, Wells G, Holiday R. Peripheral lymph flow in sheep with bacterial peritonitis: evidence for increased peripheral microvascular permeability accompanying systemic sepsis. Surgery 1985;97:685-695.
    PubMed Google Scholar
  37. Martin CM, Sibbald WJ. Modulation of hemodynamics and organ blood flow by nitric oxide synthase inhibition is not latered in normotensive, septic rats. Am J Resp Crit Care Med 1994;150:1544
    Google Scholar
  38. Bohnen JM, Matlow AG, Mustard RA, Christie NA, Kavouris B. Antibiotic efficacy in intraabdominal sepsis: a clinically relevant model. Can J Microbiol 1988;34:326
    Google Scholar
  39. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S. Divergent efficacy of antibody to tumour necrosis factor-a in intravascular and peritonitis models of sepsis. J Infect Dis 1991;163:83-88.
    PubMed Google Scholar
  40. Alexander HR, Sheppard BC, Jensen JC, et al. Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of Gram-negative sepsis. J Clin Invest 1991;88:34-39.
    PubMed Google Scholar
  41. Walley ER, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 1996; 64:4733-4738.
    PubMed Google Scholar
  42. Christou NV, Meakins JL, Gordon J, et al. The delayed hypersensitivity response and host resistance in surgical patients-20 years later. Ann Surg 1995;222:534-548.
    PubMed Google Scholar
  43. Perera PY, Chen TY, Morrison DC, Vogel SN. Detection and analysis of the 80-kd lipopolysaccharide receptor in macrophages derived from Lpsn and Lpsd mice. J Leuk Biol 1992;51:501-506.
    Google Scholar
  44. Michalek SM, Moore RN, McGhee JR, Rosenstreich DL, Merhenhagen SE. The primary role of lymphoreticular cells in the meditation of host responses to bacterial endotoxin. J Infect Dis 1980;141:55-63.
    PubMed Google Scholar
  45. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-43.
    PubMed Google Scholar
  46. Barsig J, Bundschuh DS, Hartung T, Bauhofer A, Sauer A, Wendel A. Control of fecal perotoneal infection in mice by colony-stimulating factors. J infect Dis 1996;174:790-799.
    PubMed Google Scholar
  47. Opal SM, Cross AS, Sadoff JC, et al. Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monocolonal antibodies in a neutropenic rat model of Pseudomonas sepsis. J Clin Invest 1991;88;885-890.
    PubMed Google Scholar
  48. Bronson SK, Smithies O. Altering by homologous recombination using embryonic stem cells. J Biol Chem 1994;269:27155-27158.
    PubMed Google Scholar
  49. Gu H, Marth JD, orban PC, Mossmann H, Rajewsky K. Deletion of DNA polymerase b gene segment in T cells using cell type-specific gene targeting. Science 1994;265:103-106.
    PubMed Google Scholar
  50. Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor deficient mice. Proc Natl Acad Sci USA 1997;8093-8098.
  51. Amiot F, Fitting C, Tracey KJ, Cavaillon JM, Dautry F. Lipopolysaccharide-induced cytokine cascade and lethality in LTa/TNFa-deficient mice. Mol. Med. 1997;3:864-875.
    PubMed Google Scholar
  52. Shastry BS. Genetic knockouts in mice: and update. Experientia 1995;51:1028-1039.
    PubMed Google Scholar
  53. Fan J, Marshall JC, Jimenez M, Shek PN, Zagorski J, Rotsetin OD. Hemorrhagic shock primes for incresed expression of cytokine-induced neutophil chemoattactant in the lung: role in pulmonary inflammation following lipopolysaccharide. J Immunol 1998;161:440-447.
    PubMed Google Scholar
  54. Colleti LM, Kunkel SL, Walz A, et al. Chemokine expression during hepatic ischemia/reperfusion-induced lung injury in the rat. J Clin Invest 1995;95:134-141.
    PubMed Google Scholar
  55. Abraham E, Stevens P. Effects of granulocyte colony stimulating factor in modifying mortality from Pseudomonas aeruginosa pneumonia after hemorrhage. Crit Care Med 1992;20:1127-1133.
    PubMed Google Scholar
  56. Redl HR, Schlag G. Non-human primate models of sepsis. Sepsis 1999;243-253.
  57. Sevransky JE, Shaked G, Novogrodsky A, et al. Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis. J Clin Invest 1997;99:1966-1973.
    PubMed Google Scholar
  58. Redl G, Abdi S, Traber LD, et al. Inhibition of thromboxane synthesis reduces endotoxin-induced right ventricular failure in sheep. Crit Care Med 1991;19:1294-1302.
    PubMed Google Scholar
  59. Fink MP, O'Sullivan BP, Menconi MJ, et al. Effect of granulocyte colony-stimulating factor on systemic and pulmonary responses to endotoxin in pigs. J Trauma 1993;34:571-578.
    PubMed Google Scholar
  60. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-287.
    PubMed Google Scholar
  61. Kuhns DB, Alvord WG, Gallin JI. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 1995;171:145-152.
    PubMed Google Scholar
  62. van der Poll T, de Wéal Malefyt R, Coyle SM, Lowry SF. Antiinflammatory cytokine esponses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997;175:118-122.
    PubMed Google Scholar
  63. Van Zee KJ, Coyle SM, Calvano SE, et al. Influence of IL-1 receptor blockade in the human response to endotoxemia. J Immunol 1995;154:1499-1507.
    Google Scholar
  64. Fisher CJ, Dhainaut J-FA, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-1843.
    PubMed Google Scholar
  65. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller P. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995;155:5038-5045.
    PubMed Google Scholar
  66. Fisher CJ, Jr., Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996;334:1697-1702.
    PubMed Google Scholar
  67. Pajkrt D, Manten A, van der Poll T, et al. Modulation of cytokine release and neutrophil function by grannulocyte colony-stimulating factor during endotoxemia in humans. Blood 1997;90:1415-1424.
    PubMed Google Scholar
  68. Nelson S, Belknap SM, Carlson RW, et al. A randomized controlled trial of Filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired penumonia. J Infect Dis 1998;178:1075-1080.
    PubMed Google Scholar
  69. Lin E, Cole SM, Randhawa S, et al. Polymyxin-622 prevents endotoxin-induced inflammation in humans. Surg. Forum 1998;(In Press).
  70. Wurfel MM, Monks BG, Ingalls RR, et al. Targeted deletion of the LBP gene leads to profound suppression of LPS responses ex vivo while in vivo responses remain intact. J Exp Med 1997;186:2056
    Google Scholar
  71. Jack RS, Fan X, Bernheiden M, et al. Lipopolysaccharide binding protein is required to combat a murine Gram-negative infection. Nature 1997;389:742-753.
    PubMed Google Scholar
  72. Haziot A, Ferrero E, Kontgen F, et al. Resistance to endotoxin shock and reduced dissemination of Gram negative bacteria in CD14-deficient mice. Immunity 1996;4:414.
    Google Scholar
  73. Pasparakis M, Alexopoulou A, Episkopou V, Kollias G. Immune and inflammatory responses in TNFα-deficient mice: a critical requirement for TNFα in the formation of primary B cell folicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996;184:1207-1211.
    PubMed Google Scholar
  74. Acton RD, Dahlberg PS, Uknis ME, et al. Differential sensitivity to Escherichia coli infection in mice lacking tumor necrosis factor receptor p55 or interleukin-1 p80 receptors. Arch Surg 1996;131:1216-1221.
    PubMed Google Scholar
  75. Peschon JJ, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998;160:943-952.
    PubMed Google Scholar
  76. Deckert-Schluter M, Bluethmann H, Rang A, et al. Crucial role of TNF receptor type 1 (p55), but not of TNF receptor type 2 (p75), in murine toxoplasmosis. J Immunol 1998;160:3427-3436.
    PubMed Google Scholar
  77. Fantuzzi G, Dinarello CA. The inflammatory response in interleukin-1 β-deficient mice: Comparison with other cytokine-related knock-out mice. J Leuk Biol 1996;59:489-493.
    Google Scholar
  78. Glaccum MB, Stocking KL, Charrier K, Smith JL, Willis CR, Maliszewski C, Livingston DJ, Peschon JJ, Morrissey PJ: Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol 1997;159:3364-3371.
    PubMed Google Scholar
  79. Labow M, Shuster D, Zetterstrom M, et al. Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol 1997;159:2452-2461.
    PubMed Google Scholar
  80. Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci USA 1996;93:11008-11013.
    PubMed Google Scholar
  81. Car BD, Eng VM, Schnyder B, et al. Interferon gamma receptor deficient mice are resistant to endotoxin shock. J Exp Med 1994;179:1437-1444.
    PubMed Google Scholar
  82. Kaposzta R, Tree P, Marodi L, Gordon S. Characteristics of invasive Candiasis in gamma interferon-and interleukin-4-deficient mice: role of macrophages in host defense against Candida albicans. Infect Immun 1998;66:1708-1717.
    PubMed Google Scholar
  83. Rubins JB, Pomeroy C. Role of gamma interferon in the pathogenesis of bacteremic pneumococcal pneumonia. Infect Immun 1997;65:2975-2977.
    PubMed Google Scholar
  84. Hickey MJ, Sharkey KA, Sihota EG, et al. Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. FASEB J 1997;11:955-964.
    PubMed Google Scholar
  85. Mclnnes IB, Leung B, Wei XQ, Gemell CC, Liew FY. Septic arthritis following Staphylococcus aureus infection in mice lacking inducible nitric oxide synthase. J Immunol 1998;160:308-315.
    PubMed Google Scholar

Download references